Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | AGPAT2 | O15120 | 7/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.42 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.42 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.42 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.42 |
| ▸ | CBFB | Q13951 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8901234 | 0.82 | CYP3A4 (0.50) | KDM4ENPC1RAB9AMCHR1MAPT | |
| SCHEMBL7252957 | 0.78 | SMN1; SMN2 (0.61) | KDM4ENPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL8902362 | 0.77 | EGFR (0.45) | NPC1RAB9AMCHR1MAPTMEN1 | |
| SCHEMBL8900971 | 0.77 | KDM4E (0.50) | KDM4ENPC1RAB9ASMN1; SMN2MCHR1 | |
| SCHEMBL8901413 | 0.76 | NPC1 (0.39) | KDM4ENPC1RAB9AMCHR1MAPT | |
| SCHEMBL8901370 | 0.76 | CYP2A6 (0.45) | KDM4ENPC1RAB9AMAPTMEN1 | |
| SCHEMBL8902031 | 0.73 | MAPT (0.37) | KDM4ENPC1RAB9AMCHR1MAPT | |
| SCHEMBL3415257 | 0.72 | HPGDS (0.46) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL8900856 | 0.72 | NPC1 (0.66) | KDM4ENPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL2096821 | 0.72 | RAB9A (0.62) | KDM4ENPC1RAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188284-B2 | 2-aminoquinolines | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090227583-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227583-A1 | 2-AMINOQUINOLINES | HTR5A, HTR2C, HTR2B | KDM4E 1411/4885AGPAT2 2339/4885NPC1 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.